Dr. Donald Drakeman, J.D., Ph.D., . is President and CEO of Medarex, a Nasdaq-listed biotechnology company that is developing monoclonal antibodies for the treatment of life threatening and debilitating diseases.

He is a director of Oxford GlycoSciences Plc and Immuno-Designed Molecules, S.A. Dr. Drakeman is also a member of the board of directors of the Biotechnology Council of New Jersey and the Biotechnology Industry Organization He is a trustee of the University of Charleston.